Stable Factor IX Expression and Sustained Reductions in Factor IX Use 8 Years after Gene Therapy with CSL220 (Formerly AMT-060) in Adults with Hemophilia B

作者
Frank W.G. Leebeek,Karina Meijer,Michiel Coppens,Peter Kampmann,Klamroth,Paul van der Valk,Paul E. Monahan,Karen Pinachyan,Sandra LeQuellec,Wolfgang Miesbach
出处
期刊:Blood [Elsevier BV]
卷期号:144 (Supplement 1): 3578-3578 被引量:5
标识
DOI:10.1182/blood-2024-198379
摘要

Introduction: CSL220 (formerly AMT-060) is an adeno-associated virus serotype 5 (AAV5) vector encoding a codon-optimized wild-type human factor IX (FIX) gene, driven by a liver-specific promoter. CSL220 has an identical vector sequence to etranacogene dezaparvovec (CSL222), without the activity-enhancing two nucleotide change in the human FIX coding sequence of the Padua FIX variant. The Phase I/II study included 10 patients with severe or moderately severe hemophilia B (FIX activity ≤2 IU/dL) who received a single intravenous infusion of CSL220 (5×1012 gc/kg [Cohort 1; n=5] or 2×1013 gc/kg [Cohort 2; n=5]). Nine out of ten patients were FIX concentrate prophylaxis-free after CSL220 administration. Using the one-stage activated partial thromboplastin time (aPTT) assay (HemosIL® SynthASil reagent), mean (standard deviation, SD) and median (range) FIX activities were 6.5 (0.3) IU/dL and 6.5 (6.3-6.7) IU/dL, respectively, in Cohort 1 (n=2) and 6.6 (2.0) IU/dL and 7.2 (3.8-8.3) IU/dL in Cohort 2 (n=4) at completion of the phase I/II trial (NCT02396342), 5 years post-treatment with CSL220. Continued assessment of the efficacy and safety of CSL220 is on-going in an extension study up to 10 years post-administration (NCT05360706). Methods: Patients who successfully completed all assessments during 5 years of follow-up were enrolled in the open-label, Phase I/IIb extension study. Here, we report the third year of follow-up in the extension study; representing 8 years after CSL220 administration. Four of five patients from Cohort 1 (including one patient who remained on FIX prophylaxis) and all five patients from Cohort 2 enrolled in the extension study. Results: Endogenous FIX activity (one-stage aPTT assay) remained stable at Year 8; mean (SD) and median (range) FIX activity were 4.9 (1.2) IU/dL and 5.2 (3.6-6.0) IU/dL in Cohort 1 (n=3, excluding the patient who remained on prophylaxis), and 5.6 (1.2) IU/dL and 5.8 (3.7-7.0) IU/dL in Cohort 2 (n=5), respectively. Mean (SD) annualized bleeding rate (ABR) for individual (excluding the patient who remained on prophylaxis) for Year 8 was 2.2 (2.2, n=3) and 1.0 (1.8, n=5) for Cohort 1 and 2, respectively. In Year 8, one patient in Cohort 1, and three patients in Cohort 2 experienced no bleeds. Mean (SD) annualized spontaneous bleeding rate (AsBR) was 1.5 (1.7, n=3) in Cohort 1 and 0.4 (0.9, n=5) in Cohort 2. Spontaneous bleeds were experienced by two patients in Cohort 1 and one patient in Cohort 2. One patient experienced one traumatic bleed in Cohort 1, and one patient experienced one traumatic bleed in Cohort 2. Mean (SD) annualized FIX consumption during Year 8 (excluding surgeries and the patient who remained on FIX prophylaxis) was 17,817.1 (30,860.1) IU/year (or 189.5 [328.3] IU/kg/year) in Cohort 1 (n=3) and 12,302.4 (24,223.6) IU/year (or 149.3 [300.0] IU/kg/year) in Cohort 2 (n=5). No new safety events were identified during Year 8, and no patient returned to continuous FIX prophylaxis. Conclusions: Durability of factor expression is a key consideration in the decision-making process about gene therapy for patients and physicians. With just one amino acid difference in the expressed FIX protein, CSL220 is the precursor of etranacogene dezaparvovec (CSL222), which was the first gene therapy approved for the treatment of hemophilia B. This 8-year follow-up after CSL220 administration provides continued evidence for the durability, stability, and safety of FIX expression after AAV5-based gene therapy for the treatment of hemophilia B.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
苹果星月发布了新的文献求助20
3秒前
无糖可乐完成签到,获得积分10
3秒前
Glllll完成签到 ,获得积分10
4秒前
传奇3的应助被张点心采纳,获得10
4秒前
慈蔼的人完成签到 ,获得积分10
5秒前
共享精神的应助被十七采纳,获得10
5秒前
谨慎笑阳完成签到,获得积分10
5秒前
小胡完成签到,获得积分10
6秒前
Running发布了新的文献求助10
6秒前
景琦完成签到,获得积分10
6秒前
29完成签到,获得积分10
6秒前
6秒前
8秒前
9秒前
XZJ完成签到,获得积分10
10秒前
heiehi完成签到,获得积分10
10秒前
10秒前
10秒前
搜集达人的应助被明前易拉罐采纳,获得10
11秒前
高山完成签到 ,获得积分10
12秒前
Tao完成签到 ,获得积分10
13秒前
Jaylou完成签到,获得积分0
13秒前
14秒前
充电宝的应助被MADAO采纳,获得30
14秒前
上官若男的应助被青小泥采纳,获得10
14秒前
xing发布了新的文献求助10
14秒前
万能图书馆的应助被左白易采纳,获得10
15秒前
OS完成签到 ,获得积分10
15秒前
15秒前
陈晓钱完成签到,获得积分10
17秒前
17秒前
18秒前
xiaoxia完成签到,获得积分10
18秒前
DUMPLINGS完成签到 ,获得积分10
19秒前
19秒前
hnu完成签到,获得积分20
19秒前
充电宝的应助被suzy采纳,获得10
21秒前
盛龙完成签到,获得积分10
21秒前
lky1017完成签到,获得积分10
23秒前
shjddw完成签到,获得积分10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571537
关于积分的说明 21818552
捐赠科研通 7778091
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479621